|
|
Volumn 6, Issue 12, 2009, Pages 679-680
|
|
Sunitinib in RCC - Expanded access equals expanded benefit?
a
b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IMMUNOMODULATING AGENT;
PROTEIN TYROSINE KINASE;
SORAFENIB;
SUNITINIB;
VASCULOTROPIN RECEPTOR;
ANTINEOPLASTIC AGENT;
INDOLE DERIVATIVE;
PYRROLE DERIVATIVE;
ADVANCED CANCER;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CLINICAL PRACTICE;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
DRUG UTILIZATION;
HEALTH CARE ACCESS;
HUMAN;
KIDNEY CARCINOMA;
MEDICAL AUDIT;
MEDICAL INFORMATION;
METASTASIS;
MULTIPLE CYCLE TREATMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGNOSIS;
PROGRESSION FREE SURVIVAL;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
TREATMENT DURATION;
UNSPECIFIED SIDE EFFECT;
WORK EXPERIENCE;
KIDNEY TUMOR;
NOTE;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
HUMANS;
INDOLES;
KIDNEY NEOPLASMS;
PROGNOSIS;
PYRROLES;
|
|
EID: 75649143725
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2009.170 Document Type: Short Survey |
|
Times cited : (5)
|
|
References (8)
|
